This guidance recommends steps manufacturers of APIs and drug products should take to detect and prevent unacceptable levels of nitrosamine impurities in pharmaceutical products. The guidance also describes conditions that may introduce nitrosamine impurities. The recent unexpected finding of nitrosamine impurities, which are probable human carcinogens, in drugs such as angiotensin II receptor blockers (ARBs), ranitidine, nizatidine, and metformin, has made clear the need for a risk assessment strategy for potential nitrosamines in any pharmaceutical product at risk for their presence.
Guidelines for restarting industrial units after lockdown
content for thiscontent for thiscontent for thiscontent for thiscontent for this content for thisvvvcontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for this content for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for this
Guidelines for restarting industrial units after lockdown
content for thiscontent for thiscontent for thiscontent for thiscontent for this content for thisvvvcontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for this content for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for this
Guidelines for restarting industrial units after lockdown
content for thiscontent for thiscontent for thiscontent for thiscontent for this content for thisvvvcontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for this content for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for thiscontent for this
Regulatory Services
Regulatory Intelligence
- Country
- Category
Publishing and Submission
- Global eCTD submission Publishing and submission services
- Nees Submission
- Category
- Medical Device
- Active substances master file Submission
- Certificate of suitability Submission (CEP)